Recce Pharmaceuticals Ltd.ASX: RCE

Recce Enters Second U.S. Department of Defense R&D Agreement

· Issued by Recce Pharmaceuticals Ltd.

Filed with ASX · · 4 pages · English

Summary by 6ix AI

The study will evaluate the gel's effectiveness in reducing bacterial burden in burn wounds, particularly against significant pathogens associated with infections. The gel is designed to provide rapid, broad-spectrum anti-infective action and aims to address the urgent need for new treatments for burn wound infections.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Recce Pharmaceuticals Ltd. on 6ix

Story so far

Earlier from Recce Pharmaceuticals

Later from Recce Pharmaceuticals

All Recce Pharmaceuticals news releases